Oncology

TAR-200, an investigational intravesical drug-releasing system delivering sustained gemcitabine, demonstrated high response rates and durable outcomes in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), according to results from the Phase IIb SunRISe-1 study.

Patients with chronic lymphocytic leukemia (CLL) who consistently saw the same oncologist or hematologist experienced significantly fewer emergency room visits and hospitalizations, according to a large real-world study of nearly 6,000 individuals treated with covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes and weight reduction, may offer significant benefits in improving outcomes for patients with non-small cell lung cancer (NSCLC), according to new clinical and preclinical evidence.

Immunotherapy combined with standard neoadjuvant chemotherapy has shown encouraging benefits in hormone receptor positive, HER2 negative early breast cancer, according to new evidence.

The addition of nivolumab to platinum-etoposide chemotherapy improved both progression-free and overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC), according to results from the randomized Phase II ECOG-ACRIN EA5161 trial.

Frequent ibuprofen use was associated with a reduced risk of endometrial cancer, while aspirin showed no measurable effect, according to a large cohort analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pediatric central nervous system (CNS) tumors remain among the most fatal childhood cancers, largely because the blood-brain barrier (BBB) restricts effective therapeutic delivery and worsens clinical outcomes.

A Phase I trial of a pancreatic cancer vaccine targeting mutant KRAS has demonstrated durable immune responses and promising survival outcomes in patients with minimal residual disease following standard treatment.